Thermo Fisher Scientific Net Debt Growth & History (TMO)
Thermo Fisher Scientific's net debt was $27.47B for fiscal 2025.
View full Thermo Fisher Scientific company overviewThermo Fisher Scientific annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $27.47B | $917.0M | +3.45% |
| 2024 | 2024-12-31 | $26.55B | $1.81B | +7.34% |
| 2023 | 2023-12-31 | $24.74B | $2.77B | +12.60% |
| 2022 | 2022-12-31 | $21.97B | −$7.36B | −25.08% |
| 2021 | 2021-12-31 | $29.32B | $17.10B | +139.84% |
| 2020 | 2020-12-31 | $12.23B | −$3.86B | −24.01% |
| 2019 | 2019-12-31 | $16.09B | −$796.0M | −4.71% |
| 2018 | 2018-12-31 | $16.89B | −$2.79B | −14.16% |
| 2017 | 2017-12-31 | $19.67B | $3.83B | +24.19% |
| 2016 | 2016-12-31 | $15.84B | $3.82B | +31.79% |
| 2015 | 2015-12-31 | $12.02B | −$1.20B | −9.08% |
| 2014 | 2014-12-31 | $13.22B | $8.56B | +183.62% |
| 2013 | 2013-12-31 | $4.66B | −$1.66B | −26.23% |
| 2012 | 2012-12-31 | $6.32B | $307.0M | +5.11% |
| 2011 | 2011-12-31 | $6.01B | $4.79B | +392.76% |
| 2010 | 2010-12-31 | $1.22B | $602.6M | +97.60% |
| 2009 | 2009-12-31 | $617.4M | −$105.3M | −14.57% |
| 2008 | 2008-12-31 | $722.7M | — | — |
Thermo Fisher Scientific quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-27 | $35.12B | $6.68B | +23.48% |
| Q1 2026 | 2026-03-28 | $36.82B | $9.58B | +35.18% |
| Q4 2025 | 2025-12-31 | $27.47B | $917.0M | +3.45% |
| Q3 2025 | 2025-09-27 | $29.88B | $3.32B | +12.52% |
| Q2 2025 | 2025-06-28 | $28.44B | $5.23B | +22.52% |
| Q1 2025 | 2025-03-29 | $27.24B | $1.58B | +6.15% |
| Q4 2024 | 2024-12-31 | $26.55B | $1.81B | +7.34% |
| Q3 2024 | 2024-09-28 | $26.55B | $2.21B | +9.10% |
| Q2 2024 | 2024-06-29 | $23.21B | −$2.85B | −10.94% |
| Q1 2024 | 2024-03-30 | $25.66B | $5.0M | +0.02% |
| Q4 2023 | 2023-12-31 | $24.74B | $2.77B | +12.60% |
| Q3 2023 | 2023-09-30 | $24.34B | −$893.0M | −3.54% |
| Q2 2023 | 2023-07-01 | $26.06B | −$1.30B | −4.75% |
| Q1 2023 | 2023-04-01 | $25.65B | −$2.98B | −10.42% |
| Q4 2022 | 2022-12-31 | $21.97B | −$7.36B | −25.08% |
| Q3 2022 | 2022-10-01 | $25.23B | $15.57B | +161.16% |
| Q2 2022 | 2022-07-02 | $27.36B | $15.61B | +132.79% |
| Q1 2022 | 2022-04-02 | $28.64B | $15.57B | +119.24% |
| Q4 2021 | 2021-12-31 | $29.32B | $17.10B | +139.84% |
| Q3 2021 | 2021-10-02 | $9.66B | −$3.89B | −28.72% |
| Q2 2021 | 2021-07-03 | $11.75B | −$3.74B | −24.14% |
| Q1 2021 | 2021-04-03 | $13.06B | −$3.93B | −23.11% |
| Q4 2020 | 2020-12-31 | $12.23B | −$3.86B | −24.01% |
| Q3 2020 | 2020-09-26 | $13.55B | −$2.91B | −17.70% |
| Q2 2020 | 2020-06-27 | $15.49B | −$1.93B | −11.08% |
| Q1 2020 | 2020-03-28 | $16.99B | −$697.0M | −3.94% |
| Q4 2019 | 2019-12-31 | $16.09B | −$796.0M | −4.71% |
| Q3 2019 | 2019-09-28 | $16.47B | −$1.21B | −6.84% |
| Q2 2019 | 2019-06-29 | $17.43B | −$1.06B | −5.72% |
| Q1 2019 | 2019-03-30 | $17.68B | −$2.30B | −11.51% |
| Q4 2018 | 2018-12-31 | $16.89B | −$2.79B | −14.16% |
| Q3 2018 | 2018-09-29 | $17.68B | −$3.58B | −16.83% |
| Q2 2018 | 2018-06-30 | $18.48B | $2.30B | +14.20% |
| Q1 2018 | 2018-03-31 | $19.99B | $3.63B | +22.18% |
| Q4 2017 | 2017-12-31 | $19.67B | $3.83B | +24.19% |
| Q3 2017 | 2017-09-30 | $21.25B | $4.31B | +25.43% |
| Q2 2017 | 2017-07-01 | $16.19B | $2.70B | +20.03% |
| Q1 2017 | 2017-04-01 | $16.36B | $2.15B | +15.12% |
| Q4 2016 | 2016-12-31 | $15.84B | $3.82B | +31.79% |
| Q3 2016 | 2016-10-01 | $16.94B | $4.13B | +32.28% |
| Q2 2016 | 2016-07-02 | $13.48B | $229.6M | +1.73% |
| Q1 2016 | 2016-04-02 | $14.21B | $217.0M | +1.55% |
| Q4 2015 | 2015-12-31 | $12.02B | −$1.20B | −9.08% |
| Q3 2015 | 2015-09-26 | $12.81B | −$1.13B | −8.14% |
| Q2 2015 | 2015-06-27 | $13.26B | −$1.74B | −11.59% |
| Q1 2015 | 2015-03-28 | $13.99B | −$1.87B | −11.81% |
| Q4 2014 | 2014-12-31 | $13.22B | $8.56B | +183.62% |
| Q3 2014 | 2014-09-27 | $13.94B | $8.68B | +164.78% |
| Q2 2014 | 2014-06-28 | $14.99B | $9.24B | +160.66% |
| Q1 2014 | 2014-03-29 | $15.87B | $9.71B | +157.56% |
| Q4 2013 | 2013-12-31 | $4.66B | −$1.66B | −26.23% |
| Q3 2013 | 2013-09-28 | $5.27B | −$1.41B | −21.10% |
| Q2 2013 | 2013-06-29 | $5.75B | −$48.1M | −0.83% |
| Q1 2013 | 2013-03-30 | $6.16B | $273.0M | +4.64% |
| Q4 2012 | 2012-12-31 | $6.32B | $307.0M | +5.11% |
| Q3 2012 | 2012-09-29 | $6.67B | $430.4M | +6.89% |
| Q2 2012 | 2012-06-30 | $5.80B | $3.13B | +117.12% |
| Q1 2012 | 2012-03-31 | $5.89B | $4.38B | +289.47% |
| Q4 2011 | 2011-12-31 | $6.01B | $4.79B | +392.76% |
| Q3 2011 | 2011-10-01 | $6.24B | $5.01B | +406.87% |
| Q2 2011 | 2011-07-02 | $2.67B | $1.84B | +223.31% |
| Q1 2011 | 2011-04-02 | $1.51B | $1.02B | +207.53% |
| Q4 2010 | 2010-12-31 | $1.22B | $602.6M | +97.60% |
| Q3 2010 | 2010-10-02 | $1.23B | $1.03B | +496.51% |
| Q2 2010 | 2010-07-03 | $826.2M | $226.6M | +37.79% |
| Q1 2010 | 2010-04-03 | $491.5M | — | — |
| Q4 2009 | 2009-12-31 | $617.4M | −$105.3M | −14.57% |
| Q3 2009 | 2009-09-26 | $206.5M | — | — |
| Q2 2009 | 2009-06-27 | $599.6M | — | — |
| Q4 2008 | 2008-12-31 | $722.7M | — | — |
Thermo Fisher Scientific net debt trends
Over the last five fiscal years, Thermo Fisher Scientific's net debt increased from $12.23B to $27.47B, a change of $15.24B. The latest reported quarter, Q2 2026, shows $35.12B.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Thermo Fisher Scientific source filings ↗